Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Onyvax licenses anticancer vaccine from CRCT

May 17, 1999

Ligand confirms that ECOG has initiated multicenter phase II study of Ontak for NHL

May 13, 1999

Promising phase I/II results for Leuvectin in prostate cancer presented at AUA meeting

May 5, 1999

Cantab in-licenses Novasomes adjuvant for use in TA-CIN vaccine; clinical testing in sight

April 26, 1999

Promising results reported at AACR meeting from M-Vax trial in advanced melanoma

April 21, 1999

Recombinant immunotoxin for hematological malignancies from NCI evaluated in phase I

April 20, 1999

Immunological response to GMK melanoma vaccine examined as part of phase III trial

April 19, 1999

NIH investigates next-generation cancer immunotherapeutic

April 14, 1999

Preliminary analysis of Biomira's synthetic cancer vaccine

April 13, 1999

Onyvax awarded grant for cancer vaccines

April 13, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 5, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...
How to Summit up? Dis-Harmoni on ivonescimab NSCLC phase III
BioWorld
Wall Street pundits were divided about the likely fate of ivonescimab, Summit Therapeutics Inc.’s bispecific antibody partnered with Akeso Pharmaceuticals Inc.,...